Dr. Derek Paul Bergsma, MD

Dr. Bergsma practices at Trinity Health Grand Rapids Hospital in Grand Rapids, Michigan, part of Trinity Health.

Dr. Bergsma's NPI, 1467728428, was assigned on March 23, 2012. Dr. Bergsma graduated from College of Human Medicine - Grand Rapids in 2012. Dr. Bergsma holds Michigan license 4301114117.

Dr. Bergsma's primary practice is Trinity Health Grand Rapids Hospital, at 200 Jefferson Avenue SE, Grand Rapids, MI 49503 in Kent County. The practice phone is (616) 685-5000.

Dr. Bergsma's primary practice is Trinity Health Grand Rapids Hospital in Grand Rapids, Michigan, part of Trinity Health. Dr. Bergsma is also affiliated with Corewell Health Grand Rapids Hospitals - Butterworth. The medical group on file is Trinity Health Medical Group. Dmand AI also links Dr. Bergsma to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bergsma practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Bergsma's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Bergsma is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Bergsma's licenses on file in 2 states: Michigan and New York.

Dmand AI lists bone cancer radiation, brain cancer radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, head & neck cancer radiation, lung cancer radiation and uterine cancer radiation among the conditions Dr. Bergsma treats.

CMS data shows 1,037 Medicare services from Dr. Bergsma across 15 procedure codes in 2024, for 94 Medicare patients. Medicare paid $67,637 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 94 Medicare patients who saw Dr. Bergsma in 2024. The largest group is 65 to 74, with 53 patients. 75% of them have cancer, and 73% have high cholesterol. Their average risk score is 1.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bergsma's median patient age at 71, with 27% women.

In 2024, Dr. Bergsma wrote 141 Medicare Part D claims for 73 patients. 98% of them were for generic drugs. CMS names the drug for 97 of them, across 5 drugs with 11 or more claims each, at $908 in total drug cost. In 2023, CMS named 55 claims across 4 drugs.

Dr. Bergsma accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bergsma as offering telehealth.

Dmand AI links 21 papers to Dr. Bergsma, published from 2012 to 2024. 2015 was the busiest year, with 3. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Radiotherapy Dosage. Dr. Bergsma has published most often in Int J Radiat Oncol Biol Phys. Dr. Bergsma's most frequent co-authors are Michael Matthew Dominello, DO, Peter A. Paximadis, MD and Shruti Jolly, MD.

CMS Open Payments shows 6 general payments to Dr. Bergsma from 5 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. Stryker Corporation paid the most, $172.

Dmand AI lists 2 awards for Dr. Bergsma, most recently Roentgen Resident/Fellow Research Award in 2016.

Dr. Bergsma graduated from College of Human Medicine - Grand Rapids in 2012. Dr. Bergsma is a member of ASTRO.

Dr. Bergsma is in network with 7 carriers, including Aetna, Health Alliance Plan and Priority Health. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.